Suppr超能文献

适配体:治疗应用的化学性质和修饰的综述。

Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application.

机构信息

RIBOMIC Inc., Minato-ku, Tokyo 108-0071, Japan.

The institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.

出版信息

Molecules. 2019 Nov 21;24(23):4229. doi: 10.3390/molecules24234229.

Abstract

Aptamers are short, single-stranded oligonucleotides that bind to specific target molecules. The shape-forming feature of single-stranded oligonucleotides provides high affinity and excellent specificity toward targets. Hence, aptamers can be used as analogs of antibodies. In December 2004, the US Food and Drug Administration approved the first aptamer-based therapeutic, pegaptanib (Macugen), targeting vascular endothelial growth factor, for the treatment of age-related macular degeneration. Since then, however, no aptamer medication for public health has appeared. During these relatively silent years, many trials and improvements of aptamer therapeutics have been performed, opening multiple novel directions for the therapeutic application of aptamers. This review summarizes the basic characteristics of aptamers and the chemical modifications available for aptamer therapeutics.

摘要

适配子是短的、单链的寡核苷酸,能与特定的靶分子结合。单链寡核苷酸的形状形成特征为其提供了对靶标高亲和力和极好的特异性。因此,适配子可用作抗体的类似物。2004 年 12 月,美国食品和药物管理局批准了首个基于适配子的治疗药物,即针对血管内皮生长因子的 pegaptanib(Macugen),用于治疗年龄相关性黄斑变性。然而,从那以后,还没有出现用于公共卫生的适配子药物。在这相对沉寂的几年中,已经进行了许多适配子治疗的试验和改进,为适配子的治疗应用开辟了多个新的方向。本综述总结了适配子的基本特征和可用于适配子治疗的化学修饰。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66f5/6930564/2a5a16e33bfd/molecules-24-04229-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验